Drawing for FORMA THERAPEUTICS

USPTO serial 87944961

FORMA THERAPEUTICS

Reviewed by CopyMark Law Group

Reg. 5689302Status 704Registered
Filing date
Status date
Registration date
Mar 5, 2019
Examiner
STOIDES, KATHERINE
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.

Status 704: Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active.

Need help with FORMA THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Edward T. White

Edward T. White Williams Mullen Center200 South 10th Street, Suite 1600Richmond, VA 23219UNITED STATES OF AMERICA

Goods and services

ClassDescriptionStatusFirst use
001[ chemical compounds for use in bio-pharmaceutical research ]SECTION 8 - CANCELLEDDec 1, 2008
005[ Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammation; pharmaceutical preparations for the treatment of immune-mediated conditions; pharmaceutical preparations for the treatment of neuro-degenerative diseases ]SECTION 8 - CANCELLEDFeb 28, 2018
042research and development of pharmaceuticals for others [ ; research and development of pharmaceuticals for the treatment of cancer; research and development of pharmaceuticals for the treatment of inflammations; research and development of pharmaceuticals for the treatment of immune-mediated conditions; research and development of pharmaceuticals for the treatment of neuro-degenerative diseases; scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism ]ACTIVEJun 14, 2017
044[ Providing a web site featuring information relating to the biology of potential medical treatment such as protein homeostasis, epigenetics, protein metabolism and/or immunology ]SECTION 8 - CANCELLEDJun 14, 2017

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 13, 2026NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Jan 13, 20268.PRREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED—
Jan 13, 2026PRANPOST REGISTRATION ACTION MAILED NO RESPONSE REQUIRED—
Jan 13, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Sep 4, 2025ES8RTEAS SECTION 8 RECEIVED—
Mar 5, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 10, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 10, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 10, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 10, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 10, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 14, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 14, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 14, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 14, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Apr 14, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 5, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 18, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 18, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 28, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 9, 2018PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 8, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 8, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 8, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 5, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Oct 15, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 15, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 9, 2018PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Oct 3, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 3, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 24, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 21, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Sep 21, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Sep 21, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 21, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 21, 2018CEPECOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION ENTERED—
Sep 21, 2018ALIEASSIGNED TO LIE—
Sep 21, 2018GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Sep 21, 2018GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Sep 21, 2018CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Sep 20, 2018DOCKASSIGNED TO EXAMINER—
Jun 7, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 5, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance